Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — JP Morgan Healthcare Conference 2013
22 slides from Elekta Ab Class B's conference presentation, Jan 8, 2013
Slide 1: Elekta – JP Morgan Healthcare Conference
Elekta JP Morgan Healthcare Conference 8 January 2013 Tomas Puusepp President and CEO
Slide 2: Elekta – pioneer of modern cancer care
Elekta – pioneer of modern cancer care • One of the fastest growing companies in the industry • Every year, close to 1,000,000 patients benefit from treatment with radiation therapy equipment from Elekta • Market leader in: – 3 out of 4 business areas – 2 out of 3 regions • 8-9% of net sales is inve
Slide 3: Strong growth with increased profitability
Strong growth with increased profitability SEK M Net Sales SEK M EBIT
Slide 4: Leading product portfolio with an increasing share of recurrent revenues
Leading product portfolio with an increasing share of recurrent revenues Service Aftermarket and software Hardware Net sales last 12 Leksell Gamma Knife® Service and maintenance months 43% 57% Linear accelerators (linacs) Software Brachytherapy
Slide 5: Elekta has strengthened its position in radiation therapy
Elekta has strengthened its position in radiation therapy Trend Varian 48% Elekta 39% Accuray 8% Siemens 5% Others *- Note: Order intake. Sources – company reports * Accurate data missing
Slide 6: Financial update
Financial update First half: May - October
Slide 7: Good demand, deliveries and improved cash flow
Good demand, deliveries and improved cash flow • Order bookings up 17%* during first six months – Good demand in all regions • Net sales grew 22%* – Strong deliveries • EBIT up 40% to SEK 480** M (344) • Cash flow after investments of SEK 223 M (182) – Improved working capital • Outlook unchanged *B
Slide 8: Agility – Strong demand and good progress in roll-out
AgilityTM - Strong demand and good progress in roll-out Over 100 systems delivered “Agility provides a unique combination of exceptional resolution, high speed and low leakage. This allows me as a user to adapt the treatment to any shape of tumor without compromise.” Prof. Dr. Frederik Wenz, Univers
Slide 9: Top customer satisfaction in the US
Top customer satisfaction in the US C U STOMER SATISFAC TION #1 Leksell Gamma Knife® Perfexion™ #2 Elekta Synergy® #3 Elekta Mosaiq® #4 Varian TrueBeam
Slide 10: Long-term trends
Long-term trends
Slide 11: Need for cancer care is growing
Need for cancer care is growing Number of people 60 years and older (million) North America Western Europe Emerging markets +105% +61% 103 +37% 64 63 46 2010 2030 2010 2030 Source: WHO, August 2012 Cancer Research UK
Slide 12: >50% of cancer patients in established markets to receive radiation therapy
>50% of cancer patients in established markets to receive radiation therapy Share of cancer patients receiving Recommended share of patients to radiation therapy today receive RT (CCORE) report Lung 75% USA 63% Breast 90% Europe 30-50% Colorectum Canada 32% 56% Japan 25-30% Prostate 63% Cervix uteri
Slide 13: From palliative to curative – radiotherapy is a major contributor to improved cancer care
From ”palliative” to ”curative” – radiotherapy is a major contributor to improved cancer care • Technology advancements – Imaging – Precision – Motion management – Safety • Cost effective compared with chemotherapy and surgery
Slide 14: Elekta is the pioneer of modern radiation therapy
Elekta is the pioneer of modern radiation therapy MR-guided MOSAIQ® OIS radiation Workflow software therapy for cancer care SRS Stereotactic Radiosurgery IGRT Digital linear Image guided accelerators radiation therapy Integrated solutions AgilityTM Technological shift Brachytherapy Linac SRT, in col
Slide 15: Innovation through collaboration
Innovation through collaboration Examples of R&D collaborations Elekta MR-guided linac consortium Elekta International IMRT consortium Elekta Synergy® Research Group Elekta Spine consortium Leksell Gamma Knife® Society Elekta Lung Research Group Elekta Clarity® consortium
Slide 16: Pioneering the next major breakthrough…
Pioneering the next major breakthrough… State of the art MR imaging state of the art radiation therapy • Building on a decade of research from UMC, Utrecht, NL – In collaboration with Elekta and Philips • Research demonstrated unparalleled soft tissue visualization during irradiation • Research coll
Slide 17: Emerging markets – Solid underlying growth drivers
Emerging markets - Solid underlying growth drivers Aging population 2010 2050 Male Female Male Female • Age group over 60 years will grow more than three times, from 491 in 2010 million to 1.6 billion 2050E • Government-sponsored cancer programs as main driver for expansion • Mainly greenfield proje
Slide 18: Elekta has strong performance in emerging markets
Elekta has strong performance in emerging markets Elekta emerging markets Net sales, SEK bn No. 1 CAGR No. 1 2,6 26%* 2,2 1,9 1,3 No. 1 No.1 08/09 09/10 10/11 11/12 (shared) *Excl. Nucletron CAGR is 22%
Slide 19: Double digit growth in emerging markets
Double digit growth in emerging markets Health care spend per capita and installed linacs per million inhabitants USD and units installed USA Linacs per million people Ireland Denmark Sweden1 Norway Japan Australia Switzerland Taiwan Germany Netherlands Belgium Austria UK France Italy Canada Spain S
Slide 20: Elekta in China - great success
Elekta in China - great success Now 3rd largest country in Elekta Net sales SEK M 800 700 CAGR 28% 600 500 400 300 200 Top clinics in China have 100 Elekta clinical solutions 0 FY FY FY FY 08/09 09/10 10/11 11/12 20 CAGR is 25% excluding Nucletron
Slide 21: Strong prospects for profitable growth
Strong prospects for profitable growth • Technology, innovation and clinical leadership • Extend penetration in existing markets and further improve accessibility in emerging markets • Continue to build organization and improve internal efficiencies
Slide 22: Human Care Makes the Future Possible
Human Care Makes = the Future Possible